SDF-1及CXCR4在哮喘小鼠肺组织中的表达及布地奈德的干预作用

摘要
图/表
参考文献(13)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (1209 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的：探讨哮喘小鼠发病过程中基质细胞衍生因子-1（SDF-1）及其受体CXCR4在肺内表达的变化及布地奈德的干预影响。方法：清洁级雄性BALB/c小鼠30只，随机分为对照组、干预组及哮喘组。观察卵蛋白激发及用布地奈德干预后哮喘小鼠气道的病理变化；免疫组织化学染色观察SDF-1表达的变化；RT-PCR法观察CXCR4 mRNA表达的变化。结果：SDF-1及CXCR4 mRNA在对照组中呈低表达，在哮喘组中表达明显增加，使用布地奈德进行干预后SDF-1及CXCR4 mRNA的表达明显降低（0.426±0.052 vs 0.361±0.065；0.829±0.027 vs 0.723±0.094; P<0.05），且二者表达量均与气道壁厚度呈正相关（r=0.744，P<0.01；r=0.553, P<0.01）。结论：SDF-1及其受体CXCR4可能参与了哮喘小鼠气道重塑过程，布地奈德干预改善哮喘小鼠的气道重塑可能与降低 SDF-1及CXCR的表达有关。［中国当代儿科杂志，2010，12（3）：215-218］

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	栾斌
	黄先杰
	乔俊英

关键词 ：哮喘, 气道重塑, 基质细胞衍生因子-1, CXC趋化因子受体4, 小鼠

Abstract：OBJECTIVE: To study the expression of stromal cell derived factor-1(SDF-1) and CXC chemokine receptor 4 (CXCR4) in the airway and the effect of budesonide on their expression in mice with asthma. METHODS: Thirty BALB/c male mices were randomly divided into three groups: placebo control, untreated asthma, and budesonide-treated asthma. The asthma group were induced by intraperitoneal injection of 10% ovalbumin (OVA ) on days 1, 8 and 15, and then from days 22 to 34, challenged by inhalation of 2% OVA aerosol every other day. The budesonide-treated asthma group received an inhalation of budesonide (1 mg ) before OVA challenge. The pathological changes of the airway were assessed by hematoxylin and eosin staining. The immunohistochemistry was used to estimate the expression of SDF-1 in the lung. RT-PCR was used to evaluate the expression of CXCR4 in the lung. RESULTS: Compared with the control group, SDF-1 and CXCR4 expression in the lung in the untreated asthma group increased significantly (P<0.05). The budesonide-treated asthma group demonstrated significantly decreased SDF-1 (0.426±0.052 vs 0.361±0.065; P<0.05) and CXCR4 (0.829±0.027 vs 0.723±0.094; P<0.05) expression in the lung as compared with the untreated asthma group. Both SDF-1 (r=0.744, P<0.01) and CXCR4 (r=0.553, P<0.01）were positively correlated with the thickness of the airway wall. CONCLUSIONS: SDF-1 and CXCR4 may be associated with airway remodeling in mice with asthma. Budesonide can improve airway remodeling, possibly by decreasing the expression of SDF-1 and CXCR4.［Chin J Contemp Pediatr, 2010, 12 (3):215-218］

Key words： Asthma Airway remodeling Stromal cell derived factor-1 CXC chemokine receptor 4 Mice

PACS:

R-33

引用本文:

栾斌,黄先杰,乔俊英. SDF-1及CXCR4在哮喘小鼠肺组织中的表达及布地奈德的干预作用[J]. 中国当代儿科杂志, 2010, 12(3): 215-218.

LUAN Bin,HUANG Xian-Jie,QIAO Jun-Ying. Expression of stromal cell derived factor-1 and CXC chemokine receptor 4 and the effects of budesonide on their expression in mice with asthma[J]. CJCP, 2010, 12(3): 215-218.

链接本文:

http://www.zgddek.com/CN/ 或 http://www.zgddek.com/CN/Y2010/V12/I3/215

	［1］Du Q, Chen Z, Zhou LF, Zhang Q, Huang M, Yin KS. Inhibitory effects of astragaloside Ⅳ on ovalbumin-induced chronic experimental asthma［J］. Can J Physiol. Pharmacol, 2008, 86（7）: 449-457.
	［2］Rydell-Tormanen K, Uller L, Erjefalt JS. Remodeling of extra-bronchial lung vasculature following allergic airway inflammation［J］. Respir Res, 2008, 9:18.
	［3］Locke NR, Royce SG, Wainewright JS, Samuel CS, Tang ML. Comparison of airway remodeling in acute, subacute, and chronic models of allergic airways disease［J］.Am J Respir Cell Mol Biol, 2007, 36（5）:625-632.
	［4］James AL, Wenzel S. Clinical relevance of airway remodeling in airway diseases［J］. Eur Respir J, 2007, 30（1）: 134-155.
	［5］Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoatractant, stromal cell-derived factor (SDF)［J］. J Exp Med, 1996, 184（3）: 1101-1109.
	［6］Gonzalo JA, Lloyd CM, Peled A, Delaney T, Coyle AJ, GutierrezRamos JC. Critical involvement of the chemotactic axis CXCR4/stromal cell-derived factor-1αin the Inflammatory component of allergic airway disease［J］. J Immunol, 2000, 165(1):499-508.
	［7］Hoshino M, Aoike N, Takahashi M, Nakamura Y, Nakagawa T. Increased immunoreactivity of stromal cell-derived factor-1 and angiogenesis in asthma［J］. J Eur Respir, 2003, 21（5）:804-809.
	［8］Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR, et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells［J］. Am J Pathol, 1999, 154（4）:1125-1135.
	［9］McDonald DM. Angiogenesis and remodeling of airway vasculature in chronic inflammation［J］. Am J Respir Crit Care Med, 2001,164（10 Pt 2）: S39-S45.
	［10］Eddleston J, Christiansen SC, Iuraw BL. Functional expression of the C-X-C chemokine receptor CXCR4 by human bronchial epithelial cells: regulation by proinfla-mmatory mediators［J］. J Immunol, 2002, 169(11): 6445-6451.
	［11］Nagase H, Miyamasu M, Yamaguchi M, Fujisawa T, Ohta K, Yamamoto K, et al. Expression of CXCR4 in eosinophils: functional analyses and cytokine-mediated regulation［J］. J Immunol, 2000, 164(11): 5935-5943.
	［12］Jourdan P, Abbal C, Nora N, Hori T, Uchiyama T, Vendrell JP, et al. Cutting ege: IL-4 induces functional cell-surface expression of CXCR4 on human T cells［J］. J Immunol, 1998, 160:4153-4157.
	［13］Lukacs NW, Berlin A, Schols D, Skerlj RT, Bridger GJ. AMD3100, a CXCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity［J］. Am J Patbol, 2002, 160(4):1353-1360.